In this Lungcast episode segment, Balmes spoke about advocating for air pollution improvements, inequities in air quality, and more.

Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.

Lykos Therapeutics' new drug application for MDMA plus psychiatric intervention for adults with PTSD will be the first reviewed by an FDA committee for such a therapy.

The anti-VEGF agent tarcocimab significantly improved diabetic retinopathy severity score compared with SHAM in a phase 3 study.

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

Vitamin D concentration was significant in chronic hepatitis B virus but not hepatitis C virus infection, suggesting its potential impact on immune response.

The panel emphasizes the importance of early identification of patients based on subgroups, such as those with difficult-to-control diabetes, hypertension, and bone issues, highlighting that the inability to lower a patient's insulin dosage is a significant risk factor for hypercortisolism.

Christopher Lucci, MD, reviews the current diagnostic tests for hypercortisolism, which include the Dexamethasone Suppression Test, DHEA level tests, and ACTH assessments.

In an interview, Ryan McLaughlin discussed the ethical concerns regarding treating psychiatric illness with cannabis.

Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.

The phase 2 trial failed to show improvement of ≥2-DRSS levels with the vorolanib intravitreal insert in patients with non-proliferative diabetic retinopathy.

The final in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on treatment considerations and therapeutic options for elevated Lp(a).

BI 764524 was well tolerated following intravitreal administration of single and multiple doses in the phase 1/2a trial, with signs pointing to early efficacy.

In this interview, Browning discusses his team’s trial data and the implications of the FDA’s decision to accept the supplemental new drug application for tapinarof as an eczema treatment.

Results showed the prevalence and treatment patterns for IgAN in select Asian Pacific countries and regions were not commonly available.

McIntyre explains why GLP-1/GIP receptor agonists like semaglutide may alter cognitive and psychiatric care similar to cardiometabolic disease.

Devanand reviews lecanemab and the advent of blood biomarkers for dementia and Alzheimer's management at APA 2024.

Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.

Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.

Treatment-resistant depression with intranasal esketamine was linked to improvements in major depressive disorder (MDD) symptoms and fibromyalgia pain in a 40-year-old female.

In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.

Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.

In an interview with Andrew Chen, MD, he discussed the first-line treatment for generalized anxiety disorder and when to take other alterative medication.

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder.